Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital

A Hann, W Bohle, Jan Egger, W G Zoller

Research output: Contribution to journalArticle

Abstract

Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under "real life conditions" before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic state and at least 1 cycle of chemotherapy was given. Survival was assessed until April 2016. Patients with FOLFIRINOX were further analyzed regarding drug administration and side effects. Results: 128 patients met the inclusion criteria. Of the 74 patients in the historical cohort, 62 patients received Gemcitabine. Of the 54 patients diagnosed between 2011 and June 2014, 28 patients received FOLFIRINOX and 22 Gemcitabine as the first-line chemotherapy. Only 34 % of the patients in the historical cohort received a second-line chemotherapy in comparison to 69 % in the 2011+ cohort. Median overall survival (OS) showed a survival of 13.1 months (95 % CI; 11.6 - 14.5) for the 2011+ cohort compared to 9.6 months (95 % CI; 6.1 - 13.1) in the historical group. Conclusion: This study shows a marked improvement in survival of patients diagnosed with locally advanced or metastatic PDAC in a community-based hospital during the past 4 years. The most likely reasons are the use of new polychemotherapies like FOLFIRINOX and the use of second-line chemotherapy.

LanguageEnglish
Pages1138-1142
Number of pages5
JournalZeitschrift für Gastroenterologie
Volume54
Issue number10
DOIs
StatusPublished - Oct 2016

Fingerprint

Community Hospital
Pancreatic Neoplasms
Survival
gemcitabine
Adenocarcinoma
Drug Therapy
Survival Analysis
Combination Drug Therapy
Drug-Related Side Effects and Adverse Reactions
Randomized Controlled Trials
Retrospective Studies

Cite this

Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital. / Hann, A; Bohle, W; Egger, Jan; Zoller, W G.

In: Zeitschrift für Gastroenterologie, Vol. 54, No. 10, 10.2016, p. 1138-1142.

Research output: Contribution to journalArticle

@article{98e1dc4a942e4c128b01a74f460e9e36,
title = "Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital",
abstract = "Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under {"}real life conditions{"} before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic state and at least 1 cycle of chemotherapy was given. Survival was assessed until April 2016. Patients with FOLFIRINOX were further analyzed regarding drug administration and side effects. Results: 128 patients met the inclusion criteria. Of the 74 patients in the historical cohort, 62 patients received Gemcitabine. Of the 54 patients diagnosed between 2011 and June 2014, 28 patients received FOLFIRINOX and 22 Gemcitabine as the first-line chemotherapy. Only 34 {\%} of the patients in the historical cohort received a second-line chemotherapy in comparison to 69 {\%} in the 2011+ cohort. Median overall survival (OS) showed a survival of 13.1 months (95 {\%} CI; 11.6 - 14.5) for the 2011+ cohort compared to 9.6 months (95 {\%} CI; 6.1 - 13.1) in the historical group. Conclusion: This study shows a marked improvement in survival of patients diagnosed with locally advanced or metastatic PDAC in a community-based hospital during the past 4 years. The most likely reasons are the use of new polychemotherapies like FOLFIRINOX and the use of second-line chemotherapy.",
author = "A Hann and W Bohle and Jan Egger and Zoller, {W G}",
note = "{\circledC} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2016",
month = "10",
doi = "10.1055/s-0042-110793",
language = "English",
volume = "54",
pages = "1138--1142",
journal = "Zeitschrift f{\"u}r Gastroenterologie",
issn = "0044-2771",
publisher = "Georg Thieme Verlag",
number = "10",

}

TY - JOUR

T1 - Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital

AU - Hann,A

AU - Bohle,W

AU - Egger,Jan

AU - Zoller,W G

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2016/10

Y1 - 2016/10

N2 - Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under "real life conditions" before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic state and at least 1 cycle of chemotherapy was given. Survival was assessed until April 2016. Patients with FOLFIRINOX were further analyzed regarding drug administration and side effects. Results: 128 patients met the inclusion criteria. Of the 74 patients in the historical cohort, 62 patients received Gemcitabine. Of the 54 patients diagnosed between 2011 and June 2014, 28 patients received FOLFIRINOX and 22 Gemcitabine as the first-line chemotherapy. Only 34 % of the patients in the historical cohort received a second-line chemotherapy in comparison to 69 % in the 2011+ cohort. Median overall survival (OS) showed a survival of 13.1 months (95 % CI; 11.6 - 14.5) for the 2011+ cohort compared to 9.6 months (95 % CI; 6.1 - 13.1) in the historical group. Conclusion: This study shows a marked improvement in survival of patients diagnosed with locally advanced or metastatic PDAC in a community-based hospital during the past 4 years. The most likely reasons are the use of new polychemotherapies like FOLFIRINOX and the use of second-line chemotherapy.

AB - Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under "real life conditions" before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic state and at least 1 cycle of chemotherapy was given. Survival was assessed until April 2016. Patients with FOLFIRINOX were further analyzed regarding drug administration and side effects. Results: 128 patients met the inclusion criteria. Of the 74 patients in the historical cohort, 62 patients received Gemcitabine. Of the 54 patients diagnosed between 2011 and June 2014, 28 patients received FOLFIRINOX and 22 Gemcitabine as the first-line chemotherapy. Only 34 % of the patients in the historical cohort received a second-line chemotherapy in comparison to 69 % in the 2011+ cohort. Median overall survival (OS) showed a survival of 13.1 months (95 % CI; 11.6 - 14.5) for the 2011+ cohort compared to 9.6 months (95 % CI; 6.1 - 13.1) in the historical group. Conclusion: This study shows a marked improvement in survival of patients diagnosed with locally advanced or metastatic PDAC in a community-based hospital during the past 4 years. The most likely reasons are the use of new polychemotherapies like FOLFIRINOX and the use of second-line chemotherapy.

U2 - 10.1055/s-0042-110793

DO - 10.1055/s-0042-110793

M3 - Article

VL - 54

SP - 1138

EP - 1142

JO - Zeitschrift für Gastroenterologie

T2 - Zeitschrift für Gastroenterologie

JF - Zeitschrift für Gastroenterologie

SN - 0044-2771

IS - 10

ER -